Clinical Trial Update: Irinotecan in Treating Patients With Recurrent Malignant Glioma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 clinical trial evaluating irinotecan in patients with recurrent malignant glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: New Approaches to Brain Tumor Therapy Consortium | Conditions: Brain and Central Nervous System Tumors | Phase 1, Phase 2 | Status: COMPLETED